[Multidisciplinary treatment of metastatic brain tumor and its fundamental studies for chemo-immunotherapy].
We have studied the effect of ACNU and adriamycin on rat brain tumor model innoculated by hepatoma cells (AH-7974) in relationship to blood-brain barrier. It is concluded that a drug penetrates BBB(ACNU) is more potent agent for brain metastasis than non-penetrating drug (adriamycin). T cell and its subsets were measured using monoclonal antibodies; OKT 3, 4 and 8 in 12 patients with brain metastasis during the clinical course in relationship to immunotherapy with N-CWS. It was found that these parameters seemed well correlated to the immunological state of the patients and also useful to evaluate the efficacy of immunotherapy. Seventy six cases of brain metastasis of lung cancer were treated since CT scan has been introduced. The result of our multidisciplinary treatments were analysed. Overall mean survival was 7.44 months and one, two and three years survival rate was 19.8%, 9.7% and 2.8% respectively. However mean survival was 24.7 months in the selected cases with multimodal scheduled therapy.